Finasteride for prostatic disease: an updated and comprehensive review

Bibliography

• Barry MJ, Roehrborn CG. Extracts from “Clinical Evidence”: Benign prostatic hyperplasia. BMJ 2001;323:1042-6
   PubMed Web of Science ®Google Scholar
• Mc Connell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide 1994;8:1-17
   PubMedGoogle Scholar
• Chatelain C, Denis L, Foo JKT, et al. Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In: Benign Prostatic Hyperplasia. Chatelain C, Denis L, Foo KT, et al. editors, Health Publication Ltd, Plymouth, UK; 2001. p. 519-34
   Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol 2006;176:2010-2
   PubMed Web of Science ®Google Scholar
• Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:20
   Google Scholar
• Mc Connell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74(3):505-8
   PubMed Web of Science ®Google Scholar
• Foley CL, Kirby RS. 5 Alpha-reductasi inhibitors: what's new? Curr Opin Urology 2003;31-7
   PubMedGoogle Scholar
• Roehrborn CG. 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol 2003;5(5):12-21
   Google Scholar
• Finasteride prescription drug information. Available from: www.fda.gov
   Google Scholar
• McConnell JD, Bruskewitz RC, Walsh P, et al. for The Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63
   PubMed Web of Science ®Google Scholar
• Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51(5):677-86
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
   PubMed Web of Science ®Google Scholar
• Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 2004;14(1):17-20
   PubMed Web of Science ®Google Scholar
• Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992;147(5):1298-302
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185-91
   PubMed Web of Science ®Google Scholar
• Boyle PA, Gould L, Roehrborn CG, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48(3):398-405
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999;54(4):662-9
   PubMed Web of Science ®Google Scholar
• Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49(6):839-45
   PubMed Web of Science ®Google Scholar
• Khan MA, Partin AW. Finasteride and prostate cancer. Rev Urol 2004;6(2):97-8
   PubMedGoogle Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24
   PubMed Web of Science ®Google Scholar
• Andriole GL, Humphrey PA, Serfling RJ, et al. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artefact? J Natl Cancer Inst 2007;99:1355-6
   PubMed Web of Science ®Google Scholar
• Greene D, Page T. Why do men who receive finasteride have an increased prevalence of high-grade prostate cancer? Nat Clin Pract Urol 2008;5:130-1
   PubMedGoogle Scholar
• Goodman PJ, Thompson IM, Tangen CM, et al. The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol 2006;175(6):2234-42
   PubMed Web of Science ®Google Scholar
• Redman MW, Tangen CM, Goodman PJ, et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach. Cancer Prev Res 2008;1:174-81
   PubMed Web of Science ®Google Scholar
• Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83
   PubMed Web of Science ®Google Scholar
• Lucia MS, Darke AK, Goodman PJ, et al. Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention. Cancer Prev Res 2008;1:167-73
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177(5):1749-52
   PubMed Web of Science ®Google Scholar
• Thompson IM, Chen C, Donna P, et al. Effect of Finasteride on the sensitivety of PSA for detection of prostate cancer. J Natl Cancer Inst98(16):1128-33
   PubMed Web of Science ®Google Scholar
• De Vere White. Finasteride for Chemoprevention of Prostate Cancer: Why Has It Not Been Embraced? JCO 2007;25(21):2999-3000
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025-35
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Lotan Y, Tubaro A, et al. The motion: Prevention of prostate cancer with a 5α-reductase inhibitor is feasible. Eur Urol 2006;49(2):396-400
   PubMed Web of Science ®Google Scholar
• Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65
   PubMed Web of Science ®Google Scholar
• Svatek RS, Lee JJ, Roehrborn CG, et al. Cost effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Urol Oncol 2008;26(5):564-5
   Google Scholar
• Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. BJU Int 2008;101:9333-4
   Google Scholar
• Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995;154(5):1779-82
   PubMed Web of Science ®Google Scholar
• Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998;51(2):237-40
   PubMed Web of Science ®Google Scholar
• Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002;167(6):2489-91
   PubMed Web of Science ®Google Scholar
• Holm M, Meyhoff HH. Chronic prostatic pain. A new treatment option with finasteride?” Scand J Urol Nephrol 1997;31(2):213-5
   PubMed Web of Science ®Google Scholar
• Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004;93(7):991-5
   PubMed Web of Science ®Google Scholar
• AUA guideline on management of benign prostatic hyperplasia. J Urology 2003;170:530-47
   PubMed Web of Science ®Google Scholar
• Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995;46(5):631-7
   PubMed Web of Science ®Google Scholar
• Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155(9):1251-9
   PubMed Web of Science ®Google Scholar
• Lowe FC, Mc Connell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2004;61(4):791-6
   Web of Science ®Google Scholar